Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 17, 1033-1039, November 1, 1957]
© 1957 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tarnowski, G. S.
Right arrow Articles by Stock, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tarnowski, G. S.
Right arrow Articles by Stock, C. C.

Effects of Combinations of Azaserine and of 6-Diazo-5-oxo-L-norleucine with Purine Analogs and Other Antimetabolites on the Growth of Two Mouse Mammary Carcinomas

George S. Tarnowski and C. Chester Stock

( Division of Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research, and the Sloan-Kettering Division of Cornell University Medical College, New York, N.Y.)

1. Combined treatment of mice bearing the RC mammary carcinoma with azaserine or DON, on the one hand, and 6-mercaptopurine, 6-methyl-mercaptopurine, 6-chloropurine, and thioguanine, on the other, caused a significantly greater number of complete tumor regressions and produced a synergistically increased inhibitory effect on tumor growth.
2. More tumor regressions after combined therapy were observed when treatment started on the next day following implantation of the RC carcinoma than in the cases when treatment was initiated 4 days later.
3. No synergistic therapeutic response could be elicited with these combinations of chemicals in the mouse mammary carcinoma S-790.
4. Therapy of the RC carcinoma with combinations of azaserine or DON and A-methopterin, deoxypyridoxine, N-methylformamide, ß-2-thienylalanine, or purine hydrochloride produced no synergistic therapeutic response.
5. Subcutaneous administration of cortisone to the mice bearing RC carcinoma subsequent to their treatment with 6-mercaptopurine, thioguanine, or 6-mercaptopurine and azaserine markedly decreased the number of complete tumor regressions, which observation indicated that some presumably immunogenetic factors may contribute to the causation of tumor regression in chemically treated mice.
6. Several purines, amino acids, and vitamins were tested for their ability to counteract the inhibition of growth of the RC carcinoma caused by DON. Only adenine was found to be partially effective in this respect.

Received 7/ 8/57.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1957 by the American Association for Cancer Research.